Search
19 studies match these filters. Showing 1–19 of 19 studies
| Registration number | Study | Status | Phase | Enrolment | Sites / countries | Start year | Last updated | Actions |
|---|---|---|---|---|---|---|---|---|
| NCT05268289 | Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 103 sites in total · contact listed | Recruiting | Phase 2 | 240target | 103 / 20 | 2022 | Jul 30, 2026 | |
| NCT06932263 | Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids This is a dose-range finding, double-blind, placebo-controlled, phase IIb study designed to assess efficacy and safety of tozorakimab administered subcutaneously in adult participants with uncontrolled asthma receiving medium-to-high dose inhaled corticosteroids. ✓ Contact✗ Claimed Nearest site: Hutchinson, Kansas, United States — 36 km away · 221 sites in total | Recruiting | Phase 2 | 540target | 221 / 21 | 2025 | Jul 20, 2026 | |
| NCT05491525 | Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC The purpose of this study is to evaluate the safety, efficacy, and PK of Vibegron in pediatric participants with NDO who are regularly using CIC ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 38 sites in total · contact listed | Recruiting | Phase 2 / Phase 3 | 71target | 38 / 16 | 2022 | Jun 15, 2026 | |
| NCT07764978 | Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of standard induction regimens (IsaVRd and DRd) followed by AZD0120 versus standard induction regimens followed by continuous therapy (IsaRd and DRd) in participants with newly diagnos… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 124 sites in total | Recruiting | Phase 3 | 750target | 124 / 15 | 2026 | Aug 14, 2026 | |
| NCT06172296 | Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 179 sites in total · contact listed | Recruiting | Phase 3 | 478target | 179 / 5 | 2024 | Sep 17, 2026 | |
| NCT04566328 | Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell g… ✓ Contact✗ Claimed Nearest site: Kingman, Kansas, United States — 28 km away · 647 sites in total | Recruiting | Phase 3 | 1,450target | 647 / 2 | 2021 | Aug 19, 2026 | |
| NCT07353931 | Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last abo… ✓ Contact✗ Claimed Nearest site: Newton, Kansas, United States — 53 km away · 152 sites in total · contact listed | Recruiting | Phase 3 | 900target | 152 / 14 | 2026 | Sep 8, 2026 | |
| NCT06876714 | ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complete response (pCR) after preoperative (neoadjuvant) chemotherap… ✓ Contact✗ Claimed Nearest site: Kingman, Kansas, United States — 28 km away · 690 sites in total · contact listed | Recruiting | Phase 3 | 1,524target | 690 / 2 | 2025 | Sep 2, 2026 | |
| NCT05675410 | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. Brentuximab vedotin is… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 415 sites in total · contact listed | Recruiting | Phase 3 | 1,875target | 415 / 3 | 2023 | Sep 18, 2026 | |
| NCT05812807 | Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab This phase III trial compares the effect of continuation of treatment with pembrolizumab (usual approach) to observation only at preventing cancer from coming back in patients with early-stage triple-negative breast cancer (TNBC) who achieved a pathologic complete response after preoperative chemoth… ✓ Contact✗ Claimed Nearest site: Kingman, Kansas, United States — 28 km away · 846 sites in total · contact listed | Recruiting | Phase 3 | 1,295target | 846 / 3 | 2023 | Aug 5, 2026 | |
| NCT07153471 | A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee The GZPT master protocol will support two independent studies, J2A-MC-GZT1 and J2A-MC-GZT2. Each study will see how well and safely orforglipron works in people with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 74 weeks. ✓ Contact✗ Claimed Nearest site: Newton, Kansas, United States — 53 km away · 88 sites in total · contact listed | Recruiting | Phase 3 | 800target | 88 / 7 | 2025 | Sep 8, 2026 | |
| NCT03959085 | Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab ozogamicin is a monoclonal antibody, which is a type of protei… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 231 sites in total · contact listed | Recruiting | Phase 3 | 5,951target | 231 / 5 | 2019 | Aug 25, 2026 | |
| NCT05624996 | Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or targeted therapy with osimertinib) versus the usual treatment alone… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 477 sites in total · contact listed | Recruiting | Phase 3 | 474target | 477 / 2 | 2023 | Aug 17, 2026 | |
| NCT07321652 | Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhib… ✓ Contact✗ Claimed Nearest site: Kingman, Kansas, United States — 28 km away · 210 sites in total · contact listed | Recruiting | Phase 3 | 466target | 210 / 1 | 2026 | Sep 2, 2026 | |
| NCT04267848 | Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immun… ✓ Contact✗ Claimed Nearest site: Kingman, Kansas, United States — 28 km away · 1,151 sites in total | Recruiting | Phase 3 | 1,210target | 1,151 / 2 | 2020 | Sep 8, 2026 | |
| NCT03150693 | Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a chemotherapy dr… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 460 sites in total | Recruiting | Phase 3 | 303target | 460 / 2 | 2017 | Sep 2, 2026 | |
| NCT02402244 | Project: Every Child for Younger Patients With Cancer This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care. ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 279 sites in total · contact listed | Recruiting | 75,000target | 279 / 6 | 2015 | Aug 25, 2026 | ||
| NCT03866382 | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blo… ✓ Contact✗ Claimed Nearest site: Kingman, Kansas, United States — 28 km away · 581 sites in total | Recruiting | Phase 2 | 314target | 581 / 2 | 2019 | Sep 16, 2026 | |
| NCT05334069 | Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early… ✓ Contact✗ Claimed Nearest site: Wichita, Kansas, United States — 43 km away · 745 sites in total · contact listed | Recruiting | 2,000target | 745 / 1 | 2022 | Sep 2, 2026 |